↓ Skip to main content

A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAF V600E-mutated multiple myeloma

Overview of attention for article published in Blood, April 2023
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (94th percentile)
  • High Attention Score compared to outputs of the same age and source (93rd percentile)

Mentioned by

news
4 news outlets
twitter
6 X users

Readers on

mendeley
27 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.

Login to access the Attention Digest and the Sentiment Analysis related to this output.

Timeline Attention over time Attention Score history
Login to access the full charts related to this output.
Activity
Login to access the full charts related to this output.
X Demographics

X Demographics

The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley demographics

Mendeley demographics

The data shown below were compiled from readership statistics for 27 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Login to view Mendeley reader trends over time.

Geographical breakdown

Geographical breakdown
Country Count As %
Unknown 27 100%

Demographic breakdown

Readers by professional status
Readers by professional status Count As %
Student > Master 4 15%
Other 3 11%
Student > Doctoral Student 1 4%
Researcher 1 4%
Student > Postgraduate 1 4%
Other 0 0%
Unknown 17 63%
Readers by discipline
Readers by discipline Count As %
Medicine and Dentistry 5 19%
Biochemistry, Genetics and Molecular Biology 1 4%
Business, Management and Accounting 1 4%
Computer Science 1 4%
Unknown 19 70%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 37. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 March 2023.
All research outputs
#1,120,931
of 25,837,817 outputs
Outputs from Blood
#831
of 33,771 outputs
Outputs of similar age
#23,542
of 423,009 outputs
Outputs of similar age from Blood
#15
of 247 outputs
Altmetric has tracked 25,837,817 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 33,771 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.7. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 423,009 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 247 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 93% of its contemporaries.